Latest Coronado Biosciences (CNDO) Headlines
Post# of 122
Posted On: 03/09/2014 10:27:45 AM
Latest Coronado Biosciences (CNDO) Headlines
Is A Short Squeeze Ahead for Coronado Biosciences (CNDO)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 9:24AM CST
Is A Short Squeeze Ahead for Coronado Biosciences (CNDO)?
Arkansas Leading Change in College Student Experience
Marketwire - Tue Feb 25, 6:04AM CST
Today, Achieving the Dream released Continuous Improvement for College Completion: Arkansas Builds a System-Level Strategy for Community College Student Success during a session at DREAM 2014. This report details the coordinated efforts of Arkansas that has significantly improved the progress of student outcomes at two-year colleges across the state.
5 Biotech Stocks to Trade for Breakouts
at The Street - Mon Feb 24, 1:08PM CST
Here's a technical look at five potentially explosive biotech stock plays.
Qiagen to Simplify Next-Generation Sequencing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 5:00PM CST
Qiagen recently divulged its plans to launch innovative products.
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Thursday
Coronado Shares Continue to Soar on Patent Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 4:00PM CST
The USPTO has granted a second key patent for Coronado's CNDO-109.
Coronado Biosciences Granted a Second Key Patent for CNDO-109, an Activator of Natural Killer Cells
GlobeNewswire - Thu Feb 06, 7:00AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company involved in the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, as well as the licensing and acquisition of, and investment in, development stage compounds, biologics and companies, today announced the U.S. Patent and Trademark Office (USPTO) has granted a second key patent for CNDO-109 directed to the activated Natural Killer (NK) cell compositions employed in its NK cell therapy program, and has further issued a Notice of Allowance in an additional pending application directed to pharmaceutical compositions comprising these activated NK cells. The activated NK cells are prepared by a patented process licensed by Coronado from UCL Business PLC, which is already the subject of a previously-granted U.S. patent. Similar patent protection has been obtained in Australia and India and applications are still pending in Europe, Japan and Canada.
Synthetic Biologics (SYN) Slumps: Stock Tanks 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:38AM CST
Synthetic Biologics shares fell by over 11%. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future.
Why XOMA Corporation (XOMA) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 24, 7:40AM CST
XOMA Corporation has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy
Coronado Biosciences (CNDO) Jumps: Stock Up 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 8:39AM CST
Coronado Biosciences, Inc. was a big mover last session, as its shares rose over 6% on the day.
Why Acceleron (XLRN) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 7:30AM CST
Acceleron has seen its Zacks Rank move up from Neutral to Buy over the past four weeks
5 Stocks Ready to Break Out
at The Street - Fri Jan 17, 12:24PM CST
These stocks are poised to break out and trade higher from current levels.
Impax's Outlook for 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 6:15PM CST
Impax provides financial guidelines for the current fiscal year.
Pipeline Update from XenoPort - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 5:50PM CST
XenoPort provides update on its pipeline
Zacks #1 Rank Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 8:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Thursday
AFFX, Bristol University in Array Tie-Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 1:20PM CST
Affymetrix collaborates with the University of Bristol to design wheat genotyping array.
Can the Rally in Coronado Biosciences Inc. (CNDO) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 6:46AM CST
Can the Rally in Coronado Biosciences Inc. (CNDO) Shares Continue?
Synthetic Biologics (SYN) Jumps: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 7:51AM CST
Synthetic Biologics Inc. was a big mover last session, as its shares rose over 5% on the day.
Pluristem (PSTI) Jumps: Stock Adds 8.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 7:37AM CST
Pluristem Therapeutics, Inc. was a big mover last session, as the company saw its shares nearly 9% on the day.
Is A Short Squeeze Ahead for Coronado Biosciences (CNDO)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 9:24AM CST
Is A Short Squeeze Ahead for Coronado Biosciences (CNDO)?
Arkansas Leading Change in College Student Experience
Marketwire - Tue Feb 25, 6:04AM CST
Today, Achieving the Dream released Continuous Improvement for College Completion: Arkansas Builds a System-Level Strategy for Community College Student Success during a session at DREAM 2014. This report details the coordinated efforts of Arkansas that has significantly improved the progress of student outcomes at two-year colleges across the state.
5 Biotech Stocks to Trade for Breakouts
at The Street - Mon Feb 24, 1:08PM CST
Here's a technical look at five potentially explosive biotech stock plays.
Qiagen to Simplify Next-Generation Sequencing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 5:00PM CST
Qiagen recently divulged its plans to launch innovative products.
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Thursday
Coronado Shares Continue to Soar on Patent Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 4:00PM CST
The USPTO has granted a second key patent for Coronado's CNDO-109.
Coronado Biosciences Granted a Second Key Patent for CNDO-109, an Activator of Natural Killer Cells
GlobeNewswire - Thu Feb 06, 7:00AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company involved in the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, as well as the licensing and acquisition of, and investment in, development stage compounds, biologics and companies, today announced the U.S. Patent and Trademark Office (USPTO) has granted a second key patent for CNDO-109 directed to the activated Natural Killer (NK) cell compositions employed in its NK cell therapy program, and has further issued a Notice of Allowance in an additional pending application directed to pharmaceutical compositions comprising these activated NK cells. The activated NK cells are prepared by a patented process licensed by Coronado from UCL Business PLC, which is already the subject of a previously-granted U.S. patent. Similar patent protection has been obtained in Australia and India and applications are still pending in Europe, Japan and Canada.
Synthetic Biologics (SYN) Slumps: Stock Tanks 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:38AM CST
Synthetic Biologics shares fell by over 11%. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future.
Why XOMA Corporation (XOMA) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 24, 7:40AM CST
XOMA Corporation has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy
Coronado Biosciences (CNDO) Jumps: Stock Up 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 8:39AM CST
Coronado Biosciences, Inc. was a big mover last session, as its shares rose over 6% on the day.
Why Acceleron (XLRN) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 7:30AM CST
Acceleron has seen its Zacks Rank move up from Neutral to Buy over the past four weeks
5 Stocks Ready to Break Out
at The Street - Fri Jan 17, 12:24PM CST
These stocks are poised to break out and trade higher from current levels.
Impax's Outlook for 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 6:15PM CST
Impax provides financial guidelines for the current fiscal year.
Pipeline Update from XenoPort - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 5:50PM CST
XenoPort provides update on its pipeline
Zacks #1 Rank Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 8:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Thursday
AFFX, Bristol University in Array Tie-Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 1:20PM CST
Affymetrix collaborates with the University of Bristol to design wheat genotyping array.
Can the Rally in Coronado Biosciences Inc. (CNDO) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 6:46AM CST
Can the Rally in Coronado Biosciences Inc. (CNDO) Shares Continue?
Synthetic Biologics (SYN) Jumps: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 7:51AM CST
Synthetic Biologics Inc. was a big mover last session, as its shares rose over 5% on the day.
Pluristem (PSTI) Jumps: Stock Adds 8.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 7:37AM CST
Pluristem Therapeutics, Inc. was a big mover last session, as the company saw its shares nearly 9% on the day.
(0)
(0)